In favor of a potential upward reversal we are technically very oversold right now, but we also have to acknowledge this is a rather crazy news-driven market prone to severe whipsaws.
If CAP-1002 (Deramiocel) is approved on schedule, deramiocel would become the first therapy indicated specifically for DMD-associated cardiomyopathy, addressing a critical unmet need. The StealthX(tm) exosome delivery system is a momentous change.
